JAMA Oncol:1990-2015年,世界和中国原发性肝癌发病情况有何变化?

2017-10-11 肿瘤资讯 肿瘤资讯

目前全球的肝癌负担如何?不同国家和地区引发肝癌的主要原因是什么?1990-2015年全球肝癌变化趋势又如何?近期发表的研究显示,2015年全球新发肝癌病例超过85万,肝癌死亡病例超过81万。乙肝病毒感染导致超过33%肝癌患者死亡(>26万),酒精的贡献率达到30%。这意味着大部分的肝癌可以通过疫苗接种、抗病毒治疗、安全输血及注射、减少酗酒而得到预防。

目前全球的肝癌负担如何?不同国家和地区引发肝癌的主要原因是什么?1990-2015年全球肝癌变化趋势又如何?近期发表的研究显示,2015年全球新发肝癌病例超过85万,肝癌死亡病例超过81万。乙肝病毒感染导致超过33%肝癌患者死亡(>26万),酒精的贡献率达到30%。这意味着大部分的肝癌可以通过疫苗接种、抗病毒治疗、安全输血及注射、减少酗酒而得到预防。

背景

2015年以来,肝癌成为继肺癌、结直肠癌、胃癌之后癌症死亡的第四大原因。原发性肝癌最常见的类型是肝细胞肝癌,其次是胆管癌。肝癌的疾病负担取决于暴露因素并因性别及地域而异。最主要的风险因素包括病毒感染(乙型肝炎病毒[HBV],丙型肝炎病毒[HCV],肝吸虫)、行为因素(酒精、烟草)、代谢因素(肥胖)及黄曲霉。

由于风险因素的暴露到肝癌发生存在一定的潜伏时间,即使采取最佳预防措施在一段时间内肝癌患者的数量也不会有所减少。2015年全球疾病负担分析(GBD)肝癌部分的目的有二:1提高肝癌病因随时间变化趋势的详细信息,没有这些信息是无法做到针对性预防及评估的;2促进科研及临床的战略投入。

既往关于肝癌负担的分析都只针对单一的国家、地区、年份或病因(乙肝、丙肝)。在本次的研究中,报告了2015年GBD原发性肝癌的发病率、死亡率及195个国家或地区1990-2015年伤残调整生命年(disability-adjusted life year, DALY)。

主要结果

肝癌疾病负担

2015年全球范围内有肝癌854 000例,死亡810000例。肝癌成为全球第6位的癌种,癌症死亡原因的第4位。88%的肝癌病例及86%的肝癌死亡病例发生在中/高社会人口学指数(sociodemographic index, SDI)国家。年龄标准化发病率(ASIR)在中SDI国家最高,低SDI国家次之。肝癌的发病、死亡及DALY负担最重的地区为东亚。高收入的亚太地区发病率名列第二,但死亡率、DALY则排在第三、四位。在高收入的亚太地区中,日本是这一结果的驱动力,占发病的75%,67%与HCV感染有关。西欧发病率排第三、死亡率排第四、DALY排第五。东南亚发病率随然排第四位,但是死亡率及DALY却是第二位的。2015年ASIR最高的地区是高收入的亚太国家,其次是东亚及西方撒哈拉沙漠以南的非洲。

1990-2015的变化趋势

1990-2015年,肝癌发病率增长了75%,其中年龄结构变化的贡献率为47%,人口增长因素的贡献率为35%,年龄特异性发病率对疾病总体的贡献为-8%。由于HBV相关肝癌年龄特异性发病率的降低,HBV相关肝癌的发病率下降35%,如果人口规模及年龄结构不变的话,其他原因的肝癌会上涨25%。然而,随着人口增加及老龄化,他们分别导致肝癌发病率增加42%及56%。丙肝相关及酒精相关的肝癌,总体发病率增加了114%及109%。

1990-2015年不仅在美国、加拿大、澳大利亚、新西兰及大多数欧洲国家这样的高SDI国家,而且在菲律宾、瓜地马拉、罗马尼亚和塞舌尔等地区ASIR增幅均超过100%。与此同时,在发病率较高的中国及西方国家、南非,ASIR则下降20%以上。1990-2015年年龄标准化死亡率(ASMR)在菲律宾、摩尔多瓦,和瓜地马拉增加1倍以上,而在肝癌负担较重的东亚及南非却出现了大幅下降。

性别差异

在本次肝癌病因分析中,只有14%的研究报告提及了性别对疾病的影响。综合这些信息显示,肝癌在男性中更为常见,男性vs女性:591000 vs 264000。死亡率及DALY也有类似趋势(男性vs女性,死亡率:577000 vs 234000;DALY:15 413 000 vs 5 165 000)。全球水平ASIR及ASMR男/女分别为2.5及2.8,年龄标准化DALY男/女比为3.1。ASIR男/女最高的是东亚,比列为2.9,最低的是美国安第斯拉丁,比列为0.9。全球层面HBV及酒精导致的肝癌也存在性别差异。2015年HBV导致肝癌,男性203 000例 (95% UI, 171 000-251 000),而女性仅70 000 例(95% UI, 57 000- 86 000);酒精导致肝癌,男性204 000例 (95% UI, 177 000-240 000),女性45 000例 (95% UI, 38 000-54 000)。

不同病因导致的肝癌的疾病负担

2015年,全球范围,乙肝病毒是导致肝癌发病、死亡及DALY的首要因素,其次是酒精。1990-2015年间,各种病因导致肝癌发病、死亡及DALY都在增加,增加最多的是HCV,其次是酒精。1990-2015年间,HBV所致肝癌的ASIR降低了18.9%(没有达到统计学意义),HCV所致肝癌的ASIR则增加了15.7%。酒精及其他原因导致肝癌的ASIR没有明显变化。不同国家及地区导致肝癌死亡的病因差异显着。2015年全球范围,肝癌死亡病因中,HBV占33%,酒精30%,HCV21%,其他原因16%。在拉丁美洲南部HBV感染导致肝癌死亡仅为6%,而在南非及美国安第斯拉丁则高达45%。HCV感染导致肝癌死亡在东亚最低(9%),而在高收入亚太地区最高(55%)。酒精的贡献率最低,在北非及中东部地区约13%,在东欧占53%。其他原因导致肝癌死亡的最低的地区是高收入的亚太地区(6%),最高的是大洋洲地区(27%)。在国家层面,2015年HBV导致肝癌病死率冈比亚最高为60%,墨西哥最低为4%。HCV导致肝癌病死率最高的是日本(69%),最低的是塞内加尔(7%)。酒精导致肝癌病死率最高的是白俄罗斯,最低的是伊朗。其他原因导致肝癌病死率最高的是印度尼西亚(39%),最低的是韩国(5%)。

结论

在许多国家,肝癌仍然是导致癌症死亡的主要原因之一。不同的人群肝癌的病因差别很大。本研究的结果表明,大多数的肝癌可以通过疫苗接种、抗病毒治疗、安全输血及注射、减少酗酒得到预防。根据可持续发展的目标,明确并减少风险因素有助于持续降低肝癌疾病负担。

点评

肝癌仍然是目前全球主要的公共健康问题。肝癌起病隐匿,恶性度高,治疗措施有限,患者生存期较短,因此肝癌的预防显得更为重要。通过本文的研究,可以明确各个地区最为主要的发病病因,并可以通过针对性的措施提高预防的水平,从而达到持续降低发病率及死亡率的目的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-12-16 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765027, encodeId=33721e65027bf, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 28 02:40:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865145, encodeId=ce6318651451d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 16 23:40:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799833, encodeId=dfea1e99833e3, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Jun 08 07:40:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846596, encodeId=8b651846596fe, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jan 18 17:40:00 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257486, encodeId=e469125e48682, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Oct 13 12:40:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252185, encodeId=d599252185a4, content=中国是肝癌大国.攻克肝癌任重道远., beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4c51661544, createdName=肝胆春秋, createdTime=Thu Oct 12 09:20:09 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 肝胆春秋

    中国是肝癌大国.攻克肝癌任重道远.

    0

相关资讯

Hepatology:大连化物所所在肝癌诊断型代谢标志物研究中取得新进展

近日,中科院大连化学物理研究所高分辨分离分析及代谢组学研究组(1808组)在肝癌诊断型代谢标志物研究中取得新进展,相关结果发表在《Hepatology》杂志上。

Nat Mater:癌症患者的希望“液体活检”,可早更快发现癌症

一个国际研究团队和其他机构合作,开展了一种新的诊断和预后方法,用于早期检测肝细胞癌(HCC) ,基于含有循环肿瘤DNA的简单血液样品。

FDA批准Nivolumab,肝癌开启免疫治疗新时代

9月23日,FDA批准Nivolumab(纳武单抗,以下简称O药)用于接受过索拉非尼治疗后的肝细胞癌(HCC)患者,标志着肝癌治疗正式进入免疫时代。

Onco Targets Ther:研究揭示LincRNA-p21抑制肝癌细胞迁移及侵袭的机制

既往研究发现长链非编码RNA-p21(lincRNA-p21)在肝癌(HCC)中下调,且lincRNA-p21过表达可通过诱导上皮-间质转化来抑制肿瘤侵袭。然而,其潜在的机制尚未完全阐述。本研究中,研究人员通过定量实时聚合酶链反应测定12对HCC和非肿瘤相邻正常组织中的lincRNA-p21的表达。使用表达lincRNA-p21的慢病毒载体体外研究lincRNA-p21对HCC细胞的影响。使用Sp

Nat Mater:重磅:中国学者揭示肝癌机制

今天上午,中山大学肿瘤防治中心召开肝癌早诊早治技术重大突破新闻发布会,徐瑞华教授领衔中美团队发现肝癌精准诊治新方法,破获肝癌血液“身份指纹”,研究成果于北京时间10月10日凌晨在国际学术顶尖杂志《Nature Materials》(影响因子39.737)上发表。

Sci Rep:研究发现LINC ROR或可作为侵袭性和转移性肝癌的新的治疗靶点

新的研究证据表明,长链非编码RNAs(lncRNAs)在肿瘤的发生发展中起重要作用。已知lincRNA ROR(LINC ROR)可促进人类多种癌症肿瘤的进展,包括肝细胞癌(HCC)。然而,LINC RoR在肝癌转移中的作用及其相关机制仍然完全不清楚。在本研究中,研究人员发现LINC ROR在HCC组织中的表达水平上调,高水平的LINC ROR与HCC患者预后不良相关。在功能上,LINC ROR可